Resverlogix announced end of dosing for the SUSTAIN trial May 9, 2012 and announced top-line data for SUSTAIN August 28, 2012. Resverlogix announced end of dosing for the ASSURE trial April 18, 2013 and announced top-line data for ASSURE on June 27, 2013. In advance of the SUSTAIN end of dosing announcement, a study rationale and design paper was published entitled "ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies." This first appeared online Feb 17, 2012. A couple observations. 1) Time from end of dosing to top-line for SUSTAIN and ASSURE was in the 2-4 month range; 2) Resverlogix has yet to publish a rationale and design paper for BETonMACE. Seems like a good time for this type of publication to come out for BETonMACE with end of dosing expected anytime now.

BearDownAZ